A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
Journal Information
Full Title: Alzheimers Res Ther
Abbreviation: Alzheimers Res Ther
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe informed consent form was required to be signed and dated by the subject and caregiver or study partner before exposure to any study-related procedure, including screening tests for eligibility. The Institutional Review Board (IRB; Yale University IRB, New Haven, CT) reviewed the protocol and the informed consent form. The Investigators were required to conduct all aspects of the study in accordance with all national, state and local laws of applicable Regulatory Authorities. Consent for publicationNot applicable. Competing interestsAOC, SMC, and MEH are current or former employees and shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals outside the submitted work. RSO, YH, and REC have no relevant competing interests or disclosures to report. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Roche, Genentech, UCB, and Cerevel outside the submitted work. Competing interests AOC, SMC, and MEH are current or former employees and shareholders of Cognition Therapeutics, Inc. MG is a consultant to and shareholder in Cognition Therapeutics. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals outside the submitted work. RSO, YH, and REC have no relevant competing interests or disclosures to report. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Roche, Genentech, UCB, and Cerevel outside the submitted work."
"Funding This work was supported by a grant from the National Institute on Aging (Grant # AG057553) and by Cognition Therapeutics, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."
"Trial registration The clinical trial described in this manuscript is registered at clinicaltrials.gov (NCT03493282)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025